Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study

Autor: Lene Kongsgaard Nielsen, Claudia Stege, Birgit Lissenberg-Witte, Bronno van der Holt, Ulf-Henrik Mellqvist, Morten Salomo, Gerard Bos, Mark-David Levin, Heleen Visser-Wisselaar, Markus Hansson, Annette van der Velden, Wendy Deenik, Juleon Coenen, Maja Hinge, Saskia Klein, Bea Tanis, Damian Szatkowski, Rolf Brouwer, Matthijs Westerman, Rineke Leys, Harm Sinnige, Einar Haukås, Klaas van der Hem, Marc Durian, Peter Gimsing, Niels van de Donk, Pieter Sonneveld, Anders Waage, Niels Abildgaard, Sonja Zweegman

Publikováno v: Haematologica, Vol 105, Iss 6 (2020)

Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related quality of life (HRQoL) is limited. The HOVON-87/NMSG18 study was a randomized, phase 3 study in newly diagnosed transplant ineligible patients with multip

Externí odkaz: https://doaj.org/article/ed3611ab0ceb40df9134edf248aba092

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

Autor: Henk M. Lokhorst, Ingo Schmidt-Wolf, Pieter Sonneveld, Bronno van der Holt, Hans Martin, Rene Barge, Uta Bertsch, Jana Schlenzka, Gerard M.J. Bos, Sandra Croockewit, Sonja Zweegman, Iris Breitkreutz, Peter Joosten, Christof Scheid, Marinus van Marwijk-Kooy, Hans-Juergen Salwender, Marinus H.J. van Oers, Ron Schaafsma, Ralph Naumann, Harm Sinnige, Igor Blau, Michel Delforge, Okke de Weerdt, Pierre Wijermans, Shulamiet Wittebol, Ulrich Duersen, Edo Vellenga, Hartmut Goldschmidt

Publikováno v: Haematologica, Vol 93, Iss 1 (2008)

In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adr

Externí odkaz: https://doaj.org/article/cde5267fd127455282cfd518e36718c1

Improving the identification of frail elderly newly diagnosed multiple myeloma patients

Autor: Klaas G. van der Hem, Kaz Groen, Niels W.C.J. van de Donk, Amanda C. Dijk, Nicole C. H. P. van der Burg-de Graauw, Mark-David Levin, Kazem Nasserinejad, Henriette Levenga, Paula F. Ypma, Aart Beeker, L. Strobbe, Inger S. Nijhof, Harm Sinnige, Claudia A.M. Stege, Saskia K. Klein, Roel J. W. van Kampen, Gerjo A. Velders, Ad Koster, Mels Hoogendoorn, Rineke B. L. Leys, Matthijs Westerman, Gert-Jan Timmers, Pieter Sonneveld, Marjan A. Davidis-van Schoonhoven, Sonja Zweegman, Nazik Durdu-Rayman, Matthijs H Silbermann, Ellen van der Spek, Yavuz M. Bilgin

Publikováno v: Leukemia, 35(9), 2715-2719. Nature Publishing Group
Stege, C A M, Nasserinejad, K, Klein, S K, Timmers, G J, Hoogendoorn, M, Ypma, P F, Nijhof, I S, Velders, G A, Strobbe, L, Durdu-Rayman, N, Westerman, M, Davidis-van Schoonhoven, M A, van Kampen, R J W, Beeker, A, Koster, A, Dijk, A C, van de Donk, N W C J, van der Spek, E, Leys, R B L, Silbermann, M H, Groen, K, van der Burg-de Graauw, N C H P, Sinnige, H A M, van der Hem, K G, Levenga, H, Bilgin, Y M, Sonneveld, P, Levin, M D & Zweegman, S 2021, ' Improving the identification of frail elderly newly diagnosed multiple myeloma patients ', Leukemia, vol. 35, no. 9, pp. 2715-2719 . https://doi.org/10.1038/s41375-021-01162-z

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c982e9f5732c38f73a830fb0c6796056
https://doi.org/10.1038/s41375-021-01162-z

Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS

Autor: Markus G. Manz, Harm Sinnige, Marie-Christiane Vekemans, Jürgen Kuball, Yves Chalandon, Dominik Heim, Lidwine W. Tick, Thomas Pabst, Peter E. Westerweel, Marjolein van der Poel, Dimitri Breems, Jeroen Janssen, Marie-Cecile Legdeur, Ine Moors, Carlos Graux, Rolf E. Brouwer, Wim Terpstra, Danielle van Lammeren-Venema, Dries Deeren, Johan Maertens, Okke de Weerdt, Peter A. von dem Borne, Marinus van Marwijk Kooy, Marten R. Nijziel, Arjan A. van de Loosdrecht, Mojca Jongen-Lavrencic, Mels Hoogendoorn, Florence Van Obbergh, Yvette van Norden, Anna Efthymiou, Bjørn-Tore Gjertsen, Georg Stussi, Gert J. Ossenkoppele, Margriet Oosterveld, Bart J. Biemond, Asiong Jie, Mario Bargetzi, Edo Vellenga, Marjolein van der Klift, Aurélie Jaspers, Saskia K. Klein, Olivier Spertini, Walter J.F.M. van der Velden, Urs Hess, Bob Löwenberg, Michael Gregor

Publikováno v: Cancers, vol. 13, no. 4, pp. 672
Cancers, Vol. 13, No 4 (2021) P. 672
Cancers
Volume 13
Issue 4
Cancers, 13
Janssen, J, Löwenberg, B, Manz, M, Bargetzi, M, Biemond, B, von dem Borne, P, Breems, D, Brouwer, R, Chalandon, Y, Deeren, D, Efthymiou, A, Gjertsen, B T, Graux, C, Gregor, M, Heim, D, Hess, U, Hoogendoorn, M, Jaspers, A, Jie, A, Jongen-Lavrencic, M, Klein, S, van der Klift, M, Kuball, J, van Lammeren-Venema, D, Legdeur, M C, van de Loosdrecht, A, Maertens, J, Kooy, M V M, Moors, I, Nijziel, M, van Obbergh, F, Oosterveld, M, Pabst, T, van der Poel, M, Sinnige, H, Spertini, O, Terpstra, W, Tick, L, van der Velden, W, Vekemans, M C, Vellenga, E, de Weerdt, O, Westerweel, P, Stüssi, G, van Norden, Y & Ossenkoppele, G 2021, ' Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with aml and high risk mds ', Cancers, vol. 13, no. 4, 672, pp. 1-11 . https://doi.org/10.3390/cancers13040672
Cancers, Vol. 13, no. 4, p. 672 [1-11] (2021)
Cancers, Vol 13, Iss 672, p 672 (2021)
Cancers, 13(4):672, 1-11. Multidisciplinary Digital Publishing Institute (MDPI)
Janssen, Jeroen; Löwenberg, Bob; Manz, Markus; Bargetzi, Mario; Biemond, Bart; Borne, Peter von dem; Breems, Dimitri; Brouwer, Rolf; Chalandon, Yves; Deeren, Dries; Efthymiou, Anna; Gjertsen, Bjørn-Tore; Graux, Carlos; Gregor, Michael; Heim, Dominik; Hess, Urs; Hoogendoorn, Mels; Jaspers, Aurelie; Jie, Asiong; Jongen-Lavrencic, Mojca; ... (2021). Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers, 13(4) MDPI AG 10.3390/cancers13040672
Cancers, 13, 4
Cancers, 13(4):672. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 13(4):672. MDPI AG
CANCERS

Simple Summary Treatment results of acute myeloid leukemia (AML) in elderly patients are unsatisfactory. We investigated in an open label randomized phase II study whether addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6c3557e55ce8459b851cd9c38536009
https://research.rug.nl/en/publications/b689d4dd-486c-4cc1-9c6b-e638c8aa76ce

Health-Related Quality of Life in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients Treated with Either Thalidomide or Lenalidomide-Based Regimen Until Progression (HOVON-87/NMSG18 Study): A Prospective, Open-Label, Multicenter, Randomized, Phase 3 Study

Autor: Annette W.G. van der Velden, Bronno van der Holt, Gerard M. J. Bos, Harm Sinnige, Anders Waage, Ulf-Henrik Mellqvist, Damian L. Szatkowski, Klaas G. van der Hem, Markus Hansson, Peter Gimsing, Pieter Sonneveld, Juleon Coenen, Morten Salomo, Rineke B. L. Leys, Einar Haukås, Lene Kongsgaard Nielsen, Sonja Zweegman, Mark-David Levin, Saskia K. Klein, Niels Abildgaard, Heleen Visser-Wisselaar, Wendy Deenik, Maja Hinge, Matthijs Westerman, Birgit I. Lissenberg-Witte, Claudia A.M. Stege, Niels W.C.J. van de Donk

Publikováno v: SSRN Electronic Journal.

Background: The overall survival of patients with Multiple Myeloma has improved due to effective, often continuous, therapy. However, knowledge on the impact of long term treatment on health-related quality of life (HRQoL) is limited. Methods: The HO

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b5420d8549625c8ed48baac5b90b139d
https://doi.org/10.2139/ssrn.3337896